Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
SELLAS Life Sciences Group (SLS)
NASDAQ:SLS
RESEARCH TOOLSreports
SELLAS Life Sciences Group (SLS) Stock Price & Analysis
732 Followers
SLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.03 - $5.58
Previous Close$1.17
Volume509.03K
Average Volume (3M)298.79K
Market Cap
$33.17M
Enterprise Value$20.02M
Total Cash (Recent Filing)$13.90M
Total Debt (Recent Filing)$749.00K
Price to Earnings (P/E)-0.8
Beta1.90
Next Earnings
Nov 16, 2023EPS Estimate
$0.02Last Dividend Ex-Date
Apr 27, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding28,347,920
10 Day Avg. Volume1,192,980
30 Day Avg. Volume298,785
Standard Deviation0.34
R-Squared0.13
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)12.41
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit22.24
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$4.00Price Target Upside273.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
SELLAS Life Sciences Group News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLS FAQ
What was SELLAS Life Sciences Group’s price range in the past 12 months?
SELLAS Life Sciences Group lowest stock price was $1.03 and its highest was $5.58 in the past 12 months.
What is SELLAS Life Sciences Group’s market cap?
Currently, no data Available
When is SELLAS Life Sciences Group’s upcoming earnings report date?
SELLAS Life Sciences Group’s upcoming earnings report date is Nov 16, 2023 which is in 28 days.
How were SELLAS Life Sciences Group’s earnings last quarter?
SELLAS Life Sciences Group released its earnings results on Aug 10, 2023. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.355 by $0.045.
Is SELLAS Life Sciences Group overvalued?
According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued.
Does SELLAS Life Sciences Group pay dividends?
SELLAS Life Sciences Group pays a Notavailable dividend of $7025.8 which represents an annual dividend yield of N/A. See more information on SELLAS Life Sciences Group dividends here
What is SELLAS Life Sciences Group’s EPS estimate?
SELLAS Life Sciences Group’s EPS estimate is $0.02.
How many shares outstanding does SELLAS Life Sciences Group have?
SELLAS Life Sciences Group has 28,347,920 shares outstanding.
What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?
SELLAS Life Sciences Group reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.355. Following the earnings report the stock price went down -1.274%.
Which hedge fund is a major shareholder of SELLAS Life Sciences Group?
Among the largest hedge funds holding SELLAS Life Sciences Group’s share is Highbridge Capital Management LLC. It holds SELLAS Life Sciences Group’s shares valued at N/A.
---
SELLAS Life Sciences Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (273.83% Upside)
$4.00 (273.83% Upside)
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.50%
12-Months-Change
Fundamentals
Return on Equity
-301.92%
Trailing 12-Months
Asset Growth
-42.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.
---
Top 5 ETFs holding SLS
Vanguard Total Stock Market ETF
$1.05M
iShares Core S&P Total U.S. Stock Market ETF
$2.60
Up to five ETFs with an Outperform Smart Score that hold SLS. The ETFs are listed according to market value of SLS within the ETF
---